LTF as a Potential Predictive Biomarker for Durable Benefit From First‐Line Chemo‐Immunotherapy in S...
LTF as a Potential Predictive Biomarker for Durable Benefit From First‐Line Chemo‐Immunotherapy in Small Cell Lung Cancer
About this item
Full title
Author / Creator
Shen, Shimo , Wu, Yili , Shao, Zhuowei , Li, You , Peng, Di , Li, Bing , Zhang, Zhou and Wu, Shibo
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
ABSTRACT
At present, only a limited fraction of patients with extensive‐stage small cell lung cancer (ES‐SCLC) achieve a sustained response to immune checkpoint blockade (ICB) therapy. The factors that drive therapeutic efficacy remain poorly delineated, and the field is devoid of reliable predictive biomarkers to guide personalized treatment de...
Alternative Titles
Full title
LTF as a Potential Predictive Biomarker for Durable Benefit From First‐Line Chemo‐Immunotherapy in Small Cell Lung Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12127099
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_12127099
Other Identifiers
ISSN
1347-9032,1349-7006
E-ISSN
1349-7006
DOI
10.1111/cas.70049
